Anticoagulation in special patient populations: Are special dosing considerations required?

Cleveland Clinic Journal of Medicine

Volumn 72, Issue SUPPL.1, 2004, Pages

  Michota, Franklin ^a   Merli, Geno ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; LOW MOLECULAR WEIGHT HEPARIN;

CHEMOPROPHYLAXIS; DRUG EFFECT; FEMALE; HUMAN; KIDNEY FAILURE; MORBID OBESITY; NEOPLASM; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; CHEMOPREVENTION; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE; NEOPLASMS; OBESITY, MORBID; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84884578976     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.Suppl_1.S37     Document Type: Article

References (39)

1. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003; 90:547-548.
2. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003; 31:1405-1409.
3. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002; 12: 19-24.
4. Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular- weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg 2001; 11:670-676.
5. Desjardins L, Bara L, Boutitie F, et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med 2004; 128:519-526.
6. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavyweight/ obese patients with the LMWH tinzaparin: a pharmacodynamic study. Thromb Haemost 2002; 87:817-823.
7. Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 2003; 13:249-253.
8. Montalescot G, Polle V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000; 101:1083-1086.
9. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146:33-41.
10. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001; 31:42-48.
11. Smith J, Canton EM.Weight-based administration of dalteparin in obese patients. Am J Health Syst Pharm 2003; 60:683-687.
12. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin versus enoxaparin. Chest 2004; 125:856-863.
13. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):188S-203S.
14. Cadroy Y, Pourrat J, Bladre M, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63:385-390.
15. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143:753-759.
16. Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43:586-590.
17. Sanderink G, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72:308-318.
18. Eldor A. Unexplored territories in the nonsurgical patient: a look at pregnancy. Semin Hematol 2001; 38(2 Suppl 5):39-48.
19. Greer IA. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology. Baillieres Clin Obstet Gynaecol 1997; 11:403-430.
20. Koonin L, Atrash H, Lawson H, et al. Maternal mortality surveillance, United States, 1979-1986. MMWR CDC Surveill Summ 1991; 40:1-13.
21. Bonnar J. Venous thromboembolism and pregnancy. Clin Obstet Gynaecol 1981; 8:455-473.
22. Stirling Y, Woolf L, North W, et al. Hemostasis in normal pregnancy. Thromb Haemost 1984; 52:176-182.
23. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):627S-644S.
24. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol) 1999; 11:105-110.
25. Rickles FR, Levine MN. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998; 28(Suppl 3):43-49.
26. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78:285-291.
27. Bona RD, Hickey AD, Wallace DM. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol 2000; 23:71-73.
28. Lip GYH, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3:27-34.
29. Hara Y, Steiner M, Baldini MG. Characterization of the plateletaggregating activity of tumor cells. Cancer Res 1980; 40:1217-1222.
30. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318:404-407.
31. Goodnough LT, Saito H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. Cancer 1984; 54:1264-1268.
32. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl 3):338S-400S.
33. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346:975-980.
34. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341:793-800.
35. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164:963-968.
36. Cohen A, Davidson B, Gallus A, et al. Fondaparinux for the prevention of VTE in acutely ill medical patients [abstract]. Blood 2003; 102:15a.
37. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A metaanalysis. Arch Intern Med 1995; 155:601-607.
38. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153.
39. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl 3):401S-428S.